Pfizer News and Research RSS Feed - Pfizer News and Research

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. [More]
Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. [More]
EpiPen (epinephrine) emergency kits now available at Montreal Bell Centre for treating severe allergies

EpiPen (epinephrine) emergency kits now available at Montreal Bell Centre for treating severe allergies

Pfizer Canada Inc., the distributor of EpiPen, and the Montreal Bell Centre are pleased to announce that EpiPen (epinephrine) emergency kits are now available at the Bell Centre, home of the Montreal Canadiens hockey team. The new partnership strives to offer a safeguarded environment for visitors at risk of serious allergic reactions during hockey games, concerts and other entertainment events. [More]
AAHRPP accredits three more organizations

AAHRPP accredits three more organizations

The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more organizations, including the first historically black college and university medical school and a fourth hospital in Taiwan. [More]
Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability. [More]
Keas announces launch of Health Hub for self-insured employers

Keas announces launch of Health Hub for self-insured employers

Keas, the health management leader, today announced the launch of Health Hub, the first Health Management platform for self-insured employers. [More]
Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Columbia Laboratories, Inc., today announced financial results for the three- and twelve-month periods ended December 31, 2014. [More]
Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise. [More]
Brazil's first open-access research facility to be established at UNICAMP

Brazil's first open-access research facility to be established at UNICAMP

Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world. [More]
New blood thinner reduces stroke risk in patients with atrial fibrillation

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke. [More]
Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Oxytocin may be a potential therapeutic target for improving social function in psychiatric disorders

Oxytocin may be a potential therapeutic target for improving social function in psychiatric disorders

Researchers at the Yerkes National Primate Research Center, Emory University, have shown inducing the release of brain oxytocin may be a viable therapeutic option for enhancing social function in psychiatric disorders, including autism spectrum disorders and schizophrenia. [More]
Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Today, the Damon Runyon Cancer Research Foundation held the fourth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Nicotine addiction medication produces greater reductions in smoking prior to quitting

Nicotine addiction medication produces greater reductions in smoking prior to quitting

Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared with placebo produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of treatment and at 1 year, according to a study in the February 17 issue of JAMA. [More]

Hospira announces record fourth-quarter and FY 2014 results

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full year ended Dec. 31, 2014. [More]
ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets. [More]
Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia. [More]
Gilead Sciences, Mobiquity make significant healthcare investment in London

Gilead Sciences, Mobiquity make significant healthcare investment in London

London's status as a leading centre for the life sciences, financial and digital industries has attracted significant new investment by two leading US companies, announced today as Mayor of London Boris Johnson visited Boston as part of a trade delegation to the East Coast of the USA. [More]
Diplomat to dispense FDA-approved IBRANCE (palbociclib) to treat metastatic breast cancer

Diplomat to dispense FDA-approved IBRANCE (palbociclib) to treat metastatic breast cancer

Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced today it will dispense Pfizer's new breakthrough medication, IBRANCE (palbociclib), starting tomorrow, Feb. 5. [More]
Advertisement
Advertisement